Cargando…

Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats

Conventional influenza vaccines need to be designed and manufactured yearly. However, they occasionally provide poor protection owing to antigenic mismatch. Hence, there is an urgent need to develop universal vaccines against influenza virus. Using nucleoprotein (NP) and extracellular domain of matr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wenling, Huang, Baoying, Wang, Xiuping, Tan, Wenjie, Ruan, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814692/
https://www.ncbi.nlm.nih.gov/pubmed/31240620
http://dx.doi.org/10.1007/s12250-019-00138-9
_version_ 1783463034495172608
author Wang, Wenling
Huang, Baoying
Wang, Xiuping
Tan, Wenjie
Ruan, Li
author_facet Wang, Wenling
Huang, Baoying
Wang, Xiuping
Tan, Wenjie
Ruan, Li
author_sort Wang, Wenling
collection PubMed
description Conventional influenza vaccines need to be designed and manufactured yearly. However, they occasionally provide poor protection owing to antigenic mismatch. Hence, there is an urgent need to develop universal vaccines against influenza virus. Using nucleoprotein (NP) and extracellular domain of matrix protein 2 (M2e) genes from the influenza A virus A/Beijing/30/95 (H3N2), we constructed four recombinant vaccinia virus-based influenza vaccines carrying NP fused with one or four copies of M2e genes in different orders. The recombinant vaccinia viruses were used to immunize BALB/C mice. Humoral and cellular responses were measured, and then the immunized mice were challenged with the influenza A virus A/Puerto Rico/8/34 (PR8). NP-specific humoral response was elicited in mice immunized with recombinant vaccinia viruses carrying full-length NP, while robust M2e-specific humoral response was elicited only in the mice immunized with recombinant vaccinia viruses carrying multiple copies of M2e. All recombinant viruses elicited NP- and M2e-specific cellular immune responses in mice. Only immunization with RVJ-4M2eNP induced remarkably higher levels of IL-2 and IL-10 cytokines specific to M2e. Furthermore, RVJ-4M2eNP immunization provided the highest cross-protection in mice challenged with 20 MLD(50) of PR8. Therefore, the cross-protection potentially correlates with both NP and M2e-specific humoral and cellular immune responses induced by RVJ-4M2eNP, which expresses a fusion antigen of full-length NP preceded by four M2e repeats. These results suggest that the rational fusion of NP and multiple M2e antigens is critical toward inducing protective immune responses, and the 4M2eNP fusion antigen may be employed to develop a universal influenza vaccine. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12250-019-00138-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6814692
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-68146922020-03-24 Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats Wang, Wenling Huang, Baoying Wang, Xiuping Tan, Wenjie Ruan, Li Virol Sin Research Article Conventional influenza vaccines need to be designed and manufactured yearly. However, they occasionally provide poor protection owing to antigenic mismatch. Hence, there is an urgent need to develop universal vaccines against influenza virus. Using nucleoprotein (NP) and extracellular domain of matrix protein 2 (M2e) genes from the influenza A virus A/Beijing/30/95 (H3N2), we constructed four recombinant vaccinia virus-based influenza vaccines carrying NP fused with one or four copies of M2e genes in different orders. The recombinant vaccinia viruses were used to immunize BALB/C mice. Humoral and cellular responses were measured, and then the immunized mice were challenged with the influenza A virus A/Puerto Rico/8/34 (PR8). NP-specific humoral response was elicited in mice immunized with recombinant vaccinia viruses carrying full-length NP, while robust M2e-specific humoral response was elicited only in the mice immunized with recombinant vaccinia viruses carrying multiple copies of M2e. All recombinant viruses elicited NP- and M2e-specific cellular immune responses in mice. Only immunization with RVJ-4M2eNP induced remarkably higher levels of IL-2 and IL-10 cytokines specific to M2e. Furthermore, RVJ-4M2eNP immunization provided the highest cross-protection in mice challenged with 20 MLD(50) of PR8. Therefore, the cross-protection potentially correlates with both NP and M2e-specific humoral and cellular immune responses induced by RVJ-4M2eNP, which expresses a fusion antigen of full-length NP preceded by four M2e repeats. These results suggest that the rational fusion of NP and multiple M2e antigens is critical toward inducing protective immune responses, and the 4M2eNP fusion antigen may be employed to develop a universal influenza vaccine. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12250-019-00138-9) contains supplementary material, which is available to authorized users. Springer Singapore 2019-06-25 /pmc/articles/PMC6814692/ /pubmed/31240620 http://dx.doi.org/10.1007/s12250-019-00138-9 Text en © Wuhan Institute of Virology, CAS 2019
spellingShingle Research Article
Wang, Wenling
Huang, Baoying
Wang, Xiuping
Tan, Wenjie
Ruan, Li
Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats
title Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats
title_full Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats
title_fullStr Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats
title_full_unstemmed Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats
title_short Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats
title_sort improving cross-protection against influenza virus using recombinant vaccinia vaccine expressing np and m2 ectodomain tandem repeats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814692/
https://www.ncbi.nlm.nih.gov/pubmed/31240620
http://dx.doi.org/10.1007/s12250-019-00138-9
work_keys_str_mv AT wangwenling improvingcrossprotectionagainstinfluenzavirususingrecombinantvacciniavaccineexpressingnpandm2ectodomaintandemrepeats
AT huangbaoying improvingcrossprotectionagainstinfluenzavirususingrecombinantvacciniavaccineexpressingnpandm2ectodomaintandemrepeats
AT wangxiuping improvingcrossprotectionagainstinfluenzavirususingrecombinantvacciniavaccineexpressingnpandm2ectodomaintandemrepeats
AT tanwenjie improvingcrossprotectionagainstinfluenzavirususingrecombinantvacciniavaccineexpressingnpandm2ectodomaintandemrepeats
AT ruanli improvingcrossprotectionagainstinfluenzavirususingrecombinantvacciniavaccineexpressingnpandm2ectodomaintandemrepeats